| HOME >> BIOLOGY >> TECHNOLOGY |
HAYWARD, Calif., Nov. 3 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that two of its programs (MBX-2982 and MBX-8025) have been recognized in Windhover's "Top 10 most interesting projects available for partnering" in their respective categories. MBX-2982, a potential first-in-class treatment for type 2 diabetes, was recognized in the metabolic category and MBX-8025, a potential treatment for a range of dyslipidemias, was recognized in the cardiovascular category. The selections were made by independent committees assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries.
"We are honored to receive this significant recognition for not one, but two of our current programs. This recognition underscores both MBX-2982's potential to become an important new therapy for type 2 diabetes, and MBX-8025's potential in the treatment of dyslipidemia," said Harold Van Wart, Ph.D., Chief Executive Officer of Metabolex.
The metabolic selection committee was led by Marc Wortman, contributing writer to Windhover's IN VIVO and Start-Up, and Harris Kaplan, President & CEO, and Jun Huangpu, Managing Director, of Healogix, a leading business development strategy consulting firm. The cardiovascular selection committee was led by Ed Saltzman, President, and Michael Rice, Senior Consultant, of Defined Health, a leading business development strategy consulting firm.
Drawing on the analytic resources of these organizations, the selection committees evaluated hundreds of compounds currently in development.
"Selected companies have been screened using a strict set of judging
criteria for the Top 10 award and represent what our committees considered
the most attractive metabolic and cardiovascular
'/>"/>
| SOURCE Metabolex, Inc. Copyright©2008 PR Newswire. All rights reserved |